Sepsis-induced myocardial dysfunction
Conditions
Interventions
experimental group:On the basis of infection control, fluid resuscitation, and organ function support according to the 2021 guidelines for the management of sepsis and septic shock, levosimendan was a
control group:On the basis of infection control, fluid resuscitation, and organ function support according to the 2021 guidelines for the management of sepsis and septic shock, dobutamine was added to
Sponsors
Affiliated Hospital of Hangzhou Normal University
Eligibility
Sex/Gender
All
Age
47 Years to 102 Years
Inclusion criteria
Inclusion criteria: 1.Met the diagnostic criteria of Sepsis 3.0: clinically confirmed bacterial presence or highly suspicious foci of infection; SOFA score >= 2; 2.Cardiac ultrasound suggesting LVEF 18 years old; 4.The patients and/or family members agreed to participate in the study and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1.Acute myocardial infarction; 2.Previous history of chronic heart failure; 3.Cardiac surgery; 4.Malignant arrhythmia; 5.Pericardial disease; 6.Restriction of positive inotropic drugs; 7.Combination of severe hepatic and renal dysfunction; 8. Pregnancy and breastfeeding; 9. Need for ECMO or IABP; 10.Rapid progression of the disease, within 48 hours of the start of the study, death, and can not complete the current study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 28-day mortality rate;Mean Arterial Pressure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Left ventricular ejection fraction;Troponin I;B-type natriuretic peptide;Cardiac output index;Global heart end diastolic volume index;Extravascular lung water index;Systemic vascular resistance index;Lactate;Central Venous Pressure;Heart Rate; | — |
Countries
China
Contacts
Public ContactLiang Guo
Affiliated Hospital of Hangzhou Normal University
Outcome results
None listed